Bio-Techne Corporation Insider Trading

TECH

Last 12 months

Insiders sold 437K and bought nothing on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. Director Amy E. Herr sold 320K on May 8, 70% of their stake, outside a plan. The last open-market buy by an executive or director was in May 2022.

Net open-market

−437K

0 buys · 2 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 1

executives and directors

Last open-market buy

May 2022

May 10, 2022

Get an email when TECH's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
May 8	Amy E. Herr Director	SoldNo plan	6,636	$48.28	320K	70%	Form 4
Feb 17	Amy E. Herr Director	SoldNo plan	1,976	$59.11	117K	41%	Form 4
Aug 25, 2025	Roeland Nusse Director	SoldNo plan	17,040	$56.36	960K	28%	Form 4
Aug 25, 2025	Robert V Baumgartner Director	SoldNo plan	17,040	$56.21	958K	28%	Form 4
Jun 9, 2025	Amy E. Herr Director	SoldNo plan	1,280	$49.77	64K	30%	Form 4
Feb 14, 2025	Amy E. Herr Director	SoldNo plan	1,860	$65.96	123K	38%	Form 4
Jan 27, 2025	Kim Kelderman Chief Executive Officer	SoldNo plan 2 parts	13,392	$77.28 average	$1.03M	26%	Form 4

May 8No plan
Amy E. Herr
Director · sold 6,636 at $48.28
320K
70% of stake
Feb 17No plan
Amy E. Herr
Director · sold 1,976 at $59.11
117K
41% of stake
Aug 25, 2025No plan
Roeland Nusse
Director · sold 17,040 at $56.36
960K
28% of stake
Aug 25, 2025No plan
Robert V Baumgartner
Director · sold 17,040 at $56.21
958K
28% of stake
Jun 9, 2025No plan
Amy E. Herr
Director · sold 1,280 at $49.77
64K
30% of stake
Feb 14, 2025No plan
Amy E. Herr
Director · sold 1,860 at $65.96
123K
38% of stake
Jan 27, 2025No plan
Kim Kelderman
Chief Executive Officer · sold 13,392 at avg $77.28
$1.03M
26% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch TECH, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with TECH

CompareIntrinsic value

BCRXBioCryst Pharmaceuticals Inc.

$8.24-3.85%64

RGENRepligen Corporation

$178.20-0.04%35

HALOHalozyme Therapeutics Inc.

$130.34+1.34%66

TARSTarsus Pharmaceuticals Inc.

$69.07-4.91%55

ADMAAdma Biologics Inc.

$10.48-5.67%82

KRYSKrystal Biotech Inc.

$310.84+1.90%44

TWSTTwist Bioscience Corporation

$142.58+1.63%40

IMCRImmunocore Holdings plc

$29.23-2.66%40

Held by ETFs

TECH is in 159 US ETFs. The largest of them, with TECH's weight in each:

Spot a number that looks wrong? Check it in TECH's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing TECH

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.